Hepatitis B virus functional cure in persons with HIV: what are the predictors and which novel markers are useful?
Options
BORIS DOI
Publisher DOI
PubMed ID
41417916
Description
Purpose Of Review
For individuals with hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg) loss is associated with substantially decreased risk of liver-related morbidity and mortality. In recent years, many determinants of HBsAg loss have been investigated in several studies involving persons with chronic HBV infection living with and without HIV. The purpose of this review is to summarize factors that could help predict HBsAg loss in persons with HIV (PWH).Recent Findings
Rates of HBsAg loss can be higher in PWH with HBV compared to those without HIV, which has been partially attributed to immune reconstitution after starting antiretroviral therapy. In recent years, quantitative HBsAg (qHBsAg) levels were identified as the most important single serum marker predicting HBsAg loss. Other viral markers, such as hepatitis B core-related antigen, circulating HBV RNA, and immunological markers (i.e., quantitative hepatitis B core antibody, assessment of HBV-specific immune responses, peripheral blood mononuclear cells phenotypes), might also help predict HBsAg loss in PWH with HBV, particularly for certain sub-populations.Summary
Low qHBsAg before or fast qHBsAg declines after initiating potent anti-HBV therapy has been identified as the most reliable predicting serum marker. Other markers might be useful in certain sub-populations and clinical situations.
For individuals with hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg) loss is associated with substantially decreased risk of liver-related morbidity and mortality. In recent years, many determinants of HBsAg loss have been investigated in several studies involving persons with chronic HBV infection living with and without HIV. The purpose of this review is to summarize factors that could help predict HBsAg loss in persons with HIV (PWH).Recent Findings
Rates of HBsAg loss can be higher in PWH with HBV compared to those without HIV, which has been partially attributed to immune reconstitution after starting antiretroviral therapy. In recent years, quantitative HBsAg (qHBsAg) levels were identified as the most important single serum marker predicting HBsAg loss. Other viral markers, such as hepatitis B core-related antigen, circulating HBV RNA, and immunological markers (i.e., quantitative hepatitis B core antibody, assessment of HBV-specific immune responses, peripheral blood mononuclear cells phenotypes), might also help predict HBsAg loss in PWH with HBV, particularly for certain sub-populations.Summary
Low qHBsAg before or fast qHBsAg declines after initiating potent anti-HBV therapy has been identified as the most reliable predicting serum marker. Other markers might be useful in certain sub-populations and clinical situations.
Date of Publication
2026-03-01
Publication Type
Article
Subject(s)
Keyword(s)
HBsAg loss
•
HIV
•
biomarkers
•
co-infections
•
hepatitis B virus
Language(s)
en
Contributor(s)
Additional Credits
Series
Current Opinion in HIV and AIDS
Publisher
Lippincott, Williams & Wilkins
ISSN
1746-6318
1746-630X
Access(Rights)
open.access